| Literature DB >> 10022431 |
C S Hampe1, E Ortqvist, O Rolandsson, M Landin-Olsson, C Törn, A Agren, B Persson, D B Schranz, A Lernmark.
Abstract
GAD65 autoantibodies (GAD65Ab) are important markers for type 1 (insulin-dependent) diabetes mellitus. Although most patients have GAD65Ab at the time of clinical diagnosis, there are also GAD65Ab-positive individuals in the population at low risk of developing type 1 diabetes. The aim of this study was to test the hypothesis that the GAD65Ab reactivity to GAD65 cloned from human, mouse, and rat in newly diagnosed type 1 diabetic patients differ from antibody-positive healthy individuals. Sera from 254 new-onset 0- to 34-yr-old type 1 diabetic patients and 270 controls were assayed for their reactivity to human, mouse, and rat GAD65. Among the type 1 diabetic patients there was a significant better binding of human GAD65 compared to either mouse (P = 0.03) or rat GAD65 (P = 0.0005). The preference for human GAD65 increased with increasing age at onset (P = 0.0002). This differentiation was not observed in 88 GAD65Ab-positive control subjects. Our data indicate that recognition of epitopes by GAD65Ab in type 1 diabetes is different from that in nontype 1 diabetes, GAD65Ab-positive individuals.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10022431 DOI: 10.1210/jcem.84.2.5503
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN: 0021-972X Impact factor: 5.958